Sen. Tim Scott leads bicameral letter urging FDA to reconsider gene therapy decision
deny a PRV for a one-time administered novel curative gene therapy that treats sickle cell disease … viability of an industry intent on creating novel treatments for pediatric patients with sickle cell disease and other